Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

ClinicalTrials.gov ID: NCT02393794

Public ClinicalTrials.gov record NCT02393794. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer

Study identification

NCT ID
NCT02393794
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Priyanka Sharma
Other
Enrollment
51 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 17, 2015 (Actual)
Primary completion
Jul 2026 (Estimated)
Completion
Jul 2026 (Estimated)
Last update posted
Oct 6, 2025

2015 – 2026

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
6
Facility City State ZIP Site status
University of Kansas Cancer Center - Clinical Research Center Fairway Kansas 66205 —
University of Kansas Cancer Center - West Kansas City Kansas 66112 —
University of Kansas Cancer Center - Overland Park Overland Park Kansas 66210 —
University of Kansas Cancer Center - Westwood Westwood Kansas 66205 —
University of Kansas Cancer Center - South Kansas City Missouri 64131 —
University of Kansas Cancer Center - North Kansas City Missouri 64154 —
University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri 64064 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02393794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2025 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02393794 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →